Journal
JOURNAL OF IMMUNOLOGY
Volume 179, Issue 9, Pages 5633-5638Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.179.9.5633
Keywords
-
Categories
Funding
- NIAID NIH HHS [U19 AI28147] Funding Source: Medline
- NIDCR NIH HHS [DE06746] Funding Source: Medline
- NIDDK NIH HHS [DK060132, DK071176] Funding Source: Medline
Ask authors/readers for more resources
Mucosal administration of Ags induces specific Abs in external secretions and systemic unresponsiveness termed oral or mucosal tolerance. The dominant response depends on the species studied, the nature, dose, frequency, route of Ag application, and the use of adjuvants. The temporal sequence of Ag exposure determines the quality of the ensuing immune response; although initial mucosal Ag exposure results in systemic T cell hyporesponsiveness, preexisting systemic responses are refractory to the tolerizing effects of mucosal Ag encounter. Mucosal and systemic humoral responses may be induced concomitantly with diminished systemic T cell responses, thereby permitting Ab-mediated containment of mucosal Ags without stimulation of the systemic immune compartment. B cell Ig isotype switching and differentiation toward IgA production share common regulatory mechanisms with the suppression of T cells. Optimization of mucosal vaccination strategies has the potential for enhancing protective immune responses and suppressing systemic responses to autoantigens desirable for the treatment of autoimmune diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available